The Global Alliance for TB Drug Development Gerald J. Siuta, Ph.D., CLP
Public/Private Partnerships in Global Health Initiatives Gerald J. Siuta, Ph.D., CLP
description
Transcript of Public/Private Partnerships in Global Health Initiatives Gerald J. Siuta, Ph.D., CLP
![Page 1: Public/Private Partnerships in Global Health Initiatives Gerald J. Siuta, Ph.D., CLP](https://reader035.fdocuments.us/reader035/viewer/2022070417/56815455550346895dc26e6d/html5/thumbnails/1.jpg)
Public/Private Partnerships in Global Health Initiatives
Gerald J. Siuta, Ph.D., CLPConsultant, Business Development
New York University Global Health AllianceNew York City, NY
March 27, 2009
![Page 2: Public/Private Partnerships in Global Health Initiatives Gerald J. Siuta, Ph.D., CLP](https://reader035.fdocuments.us/reader035/viewer/2022070417/56815455550346895dc26e6d/html5/thumbnails/2.jpg)
Global Tuberculosis Epidemic• One-third of the world’s population is infected with
Mycobacterium tuberculosis (M.tb.)– 2 billion people
• 8-9 million develop active disease annually• 2 million deaths occur each year
– 1 person dies every 15 seconds
• 400,000 cases of MDR-TB each year• Leading cause of death in HIV-positive people
– 12 Million people are TB/HIV co-infected
TB’s economic toll: $16 billion a year
![Page 3: Public/Private Partnerships in Global Health Initiatives Gerald J. Siuta, Ph.D., CLP](https://reader035.fdocuments.us/reader035/viewer/2022070417/56815455550346895dc26e6d/html5/thumbnails/3.jpg)
Current TB Drug Therapy• Active TB
– Standard therapy – 4 drugs (isoniazid, rifampin, pyrazinamide & ethambutol) for 2 months, followed by isoniazid and rifampin for 4 months
• Latent TB– Standard therapy – isoniazid for 9 months
• Multi-Drug Resistant TB (MDR-TB)– Individualized, prolonged therapy, few available drugs, poorly
tolerated and difficult to administer• TB/HIV Co-Infection
– Treatment as in active TB, but drug interactions with antiretroviral agents make simultaneous therapy difficult
• Extensively Drug Resistant TB (XDR-TB)– No treatment available
![Page 4: Public/Private Partnerships in Global Health Initiatives Gerald J. Siuta, Ph.D., CLP](https://reader035.fdocuments.us/reader035/viewer/2022070417/56815455550346895dc26e6d/html5/thumbnails/4.jpg)
The Need for New TB Drugs
• Complex 6-9 months treatment with a 4 drug combination regimen
• No new anti-TB drug in over 40 years
• TB/HIV co-infections fueling each other
• MDR-TB is on the rise
• Unattractive market for private sector
• No capitalization of public sector research
![Page 5: Public/Private Partnerships in Global Health Initiatives Gerald J. Siuta, Ph.D., CLP](https://reader035.fdocuments.us/reader035/viewer/2022070417/56815455550346895dc26e6d/html5/thumbnails/5.jpg)
History of the TB Alliance• Cape Town Declaration – February 2000
– Hosts: Rockefeller Foundation and the Medical Research Council of South Africa
– Over 120 organizations (health, science, philanthropy and private industry)
• Results – Support goals of Stop TB Initiative– Create Scientific Blueprint– Develop Pharmacoeconomic Analysis
Build a Global Alliance forTB Drug Development
![Page 6: Public/Private Partnerships in Global Health Initiatives Gerald J. Siuta, Ph.D., CLP](https://reader035.fdocuments.us/reader035/viewer/2022070417/56815455550346895dc26e6d/html5/thumbnails/6.jpg)
The TB Alliance• Independent, international Product Development
Partnership founded in October 2000• Non-profit organization• Headquarters in New York City
– Offices in Brussels and Cape Town
• Entrepreneurial, virtual R&D approach– Out-source R&D to public and private partners
• Pro-active fundraising– Over US $200 million raised
• Support ~ 200 FTE worldwide and 38 FTE in-house
![Page 7: Public/Private Partnerships in Global Health Initiatives Gerald J. Siuta, Ph.D., CLP](https://reader035.fdocuments.us/reader035/viewer/2022070417/56815455550346895dc26e6d/html5/thumbnails/7.jpg)
Our Mission
• Develop an entirely new therapeutic regimen that will shorten or simplify the treatment of tuberculosis
• Coordinate and act as catalyst for global TB drug development activities
• Ensure Affordability, Adoption and Access (AAA Strategy)
![Page 8: Public/Private Partnerships in Global Health Initiatives Gerald J. Siuta, Ph.D., CLP](https://reader035.fdocuments.us/reader035/viewer/2022070417/56815455550346895dc26e6d/html5/thumbnails/8.jpg)
AAA Strategy
• Affordability– Appropriate pricing in developing countries
• Adoption– Ensure that new drugs are incorporated into
existing treatment programs
• Access– Procurement and distribution to those patients
who need them most
![Page 9: Public/Private Partnerships in Global Health Initiatives Gerald J. Siuta, Ph.D., CLP](https://reader035.fdocuments.us/reader035/viewer/2022070417/56815455550346895dc26e6d/html5/thumbnails/9.jpg)
Our VisionFDCs
10 Days
2 Months
6 Months
![Page 10: Public/Private Partnerships in Global Health Initiatives Gerald J. Siuta, Ph.D., CLP](https://reader035.fdocuments.us/reader035/viewer/2022070417/56815455550346895dc26e6d/html5/thumbnails/10.jpg)
Profile of a New TB Drug
• Shorten treatment to less than 2 months
• Novel mechanism of action (MDR/XDR-TB)
• Orally active
• Once daily or intermittent therapy
• Compatible with HIV treatment
• Low cost of goods
![Page 11: Public/Private Partnerships in Global Health Initiatives Gerald J. Siuta, Ph.D., CLP](https://reader035.fdocuments.us/reader035/viewer/2022070417/56815455550346895dc26e6d/html5/thumbnails/11.jpg)
Financial Support
• Bill and Melinda Gates Foundation
• Rockefeller Foundation
• Netherlands Ministry for Development Cooperation
• United States Agency for International Development (USAID)
• Governments of Great Britain and Ireland
![Page 12: Public/Private Partnerships in Global Health Initiatives Gerald J. Siuta, Ph.D., CLP](https://reader035.fdocuments.us/reader035/viewer/2022070417/56815455550346895dc26e6d/html5/thumbnails/12.jpg)
Types of Deals
• In-Licensing
• IP Assignment
• Sponsored R&D
• Collaborative R&D
• Freedom to Operate
• Clinical Trials
![Page 13: Public/Private Partnerships in Global Health Initiatives Gerald J. Siuta, Ph.D., CLP](https://reader035.fdocuments.us/reader035/viewer/2022070417/56815455550346895dc26e6d/html5/thumbnails/13.jpg)
Industrial Partners
• Bayer HealthCare
• Chiron/Novartis
• GlaxoSmithKline
• Novartis Institute for Tropical Diseases
• sanofi-aventis
![Page 14: Public/Private Partnerships in Global Health Initiatives Gerald J. Siuta, Ph.D., CLP](https://reader035.fdocuments.us/reader035/viewer/2022070417/56815455550346895dc26e6d/html5/thumbnails/14.jpg)
Academic Partners• Infectious Disease Research Institute• Institute of Materia Medica (China)• Johns Hopkins University• Korea Research Institute of Chemical
Technology/Yonsei University (South Korea)• Rutgers, The State University of New Jersey• Texas A&M University• University of Auckland (New Zealand)• University of Illinois at Chicago• University of Pennsylvania
![Page 15: Public/Private Partnerships in Global Health Initiatives Gerald J. Siuta, Ph.D., CLP](https://reader035.fdocuments.us/reader035/viewer/2022070417/56815455550346895dc26e6d/html5/thumbnails/15.jpg)
Lead Identification
Lead Optimizati
onPreclinical Phase I Phase II Phase III
Malate Synthase Inhibitors
Riminophenazines
Focused Screening
InhA Inhibitors
Mycobacterial Gyrase Inhibitors
Pleuromutilins
Nitroimidazoles
Quinolone TBK-613
Multifunctional Molecules
PA-824
Moxifloxacin
TB Alliance PortfolioTB ALLIANCE TB ALLIANCE PROGRAMSPROGRAMS
DISCOVERYDISCOVERY CLINICALCLINICAL DEVELOPMENTDEVELOPMENT
Phenotypic Screening
Protease Inhibitors
Energy Metabolism Inhibitors
NITD Portfolio
RNA Polymerase Inhibitors
![Page 16: Public/Private Partnerships in Global Health Initiatives Gerald J. Siuta, Ph.D., CLP](https://reader035.fdocuments.us/reader035/viewer/2022070417/56815455550346895dc26e6d/html5/thumbnails/16.jpg)
Bayer HealthCare
• Moxifloxacin
• Fluoroquinolone antibiotic
• Orally active
• Once-a-day dosage
• Approved in 104 countries for the treatment of bacterial respiratory and skin infections
![Page 17: Public/Private Partnerships in Global Health Initiatives Gerald J. Siuta, Ph.D., CLP](https://reader035.fdocuments.us/reader035/viewer/2022070417/56815455550346895dc26e6d/html5/thumbnails/17.jpg)
Bayer HealthCare
• Moxifloxacin
• Fluoroquinolone antibiotic
• Orally active
• Once-a-day dosage
• Approved in 104 countries for the treatment of bacterial respiratory and skin infections
![Page 18: Public/Private Partnerships in Global Health Initiatives Gerald J. Siuta, Ph.D., CLP](https://reader035.fdocuments.us/reader035/viewer/2022070417/56815455550346895dc26e6d/html5/thumbnails/18.jpg)
Moxifloxacin for TB
• Novel mechanism of action: kills M.tb. by inhibition of DNA gyrase
• In vivo studies showed moxifloxacin reduced treatment time by two months when substituted for isoniazid
• Safe to use with antiretroviral agents since it is not metabolized by the cytochrome P-450 enzyme system
![Page 19: Public/Private Partnerships in Global Health Initiatives Gerald J. Siuta, Ph.D., CLP](https://reader035.fdocuments.us/reader035/viewer/2022070417/56815455550346895dc26e6d/html5/thumbnails/19.jpg)
The Partnership
• Clinically assess the efficacy and safety of moxifloxacin as a front-line agent for the treatment of TB
• If clinical trials are successful, register moxifloxacin for a TB indication
• Committed to making the product affordable and accessible to patients in the developing world
![Page 20: Public/Private Partnerships in Global Health Initiatives Gerald J. Siuta, Ph.D., CLP](https://reader035.fdocuments.us/reader035/viewer/2022070417/56815455550346895dc26e6d/html5/thumbnails/20.jpg)
Moxifloxacin Clinical Trials
• Evaluate whether substitution of moxifloxacin for one of the standard TB drugs (isoniazid or ethambutol) eliminates TB infection faster than current therapy
• Trials to be run in Brazil, Canada, South Africa, Spain, Tanzania, Uganda, the United States and Zambia
• More than 3,000 TB patients to be enrolled
![Page 21: Public/Private Partnerships in Global Health Initiatives Gerald J. Siuta, Ph.D., CLP](https://reader035.fdocuments.us/reader035/viewer/2022070417/56815455550346895dc26e6d/html5/thumbnails/21.jpg)
Bayer Commitments
• Donate moxifloxacin for each clinical trial site
• Cover costs of regulatory filings
• Provide moxifloxacin at an affordable price for patients with TB in the developing world
![Page 22: Public/Private Partnerships in Global Health Initiatives Gerald J. Siuta, Ph.D., CLP](https://reader035.fdocuments.us/reader035/viewer/2022070417/56815455550346895dc26e6d/html5/thumbnails/22.jpg)
TB Alliance Commitments• Coordinate and help cover the costs of the
clinical trials• Ensure coordination of information and
results towards the goal of registration• Leverage substantial support from:
– U.S. Centers for Disease Control and Prevention (CDC)
– Orphan Products Development Center of the U.S. Food & Drug Administration
– European and Developing Countries Clinical Trials Partnership (EDCTP)
![Page 23: Public/Private Partnerships in Global Health Initiatives Gerald J. Siuta, Ph.D., CLP](https://reader035.fdocuments.us/reader035/viewer/2022070417/56815455550346895dc26e6d/html5/thumbnails/23.jpg)
Chiron/Novartis
• PA-824 – A novel nitroimidazole
• Discovered by Pathogenesis, Inc.
• Distinct mechanism of action
• Potent activity against both active and slow growing M.tb.
• Possesses both bactericidal and sterilizing activity
![Page 24: Public/Private Partnerships in Global Health Initiatives Gerald J. Siuta, Ph.D., CLP](https://reader035.fdocuments.us/reader035/viewer/2022070417/56815455550346895dc26e6d/html5/thumbnails/24.jpg)
Chiron/Novartis
• Worldwide exclusive license for the treatment of tuberculosis
• Defined scientific milestones
• Grant-back option
• Manufacturing rights
• No royalties in developing world
![Page 25: Public/Private Partnerships in Global Health Initiatives Gerald J. Siuta, Ph.D., CLP](https://reader035.fdocuments.us/reader035/viewer/2022070417/56815455550346895dc26e6d/html5/thumbnails/25.jpg)
Korea Research Institute of Chemical Technology (KRICT)
• Located in Daejeon, South Korea
• Synthesized more than 600 quinolones, pyridones & quinolizines
• In vitro and in vivo biological testing at the Yonsei University College of Medicine in Seoul, South Korea
• One lead compound has been selected for further preclinical evaluation
![Page 26: Public/Private Partnerships in Global Health Initiatives Gerald J. Siuta, Ph.D., CLP](https://reader035.fdocuments.us/reader035/viewer/2022070417/56815455550346895dc26e6d/html5/thumbnails/26.jpg)
University of Auckland
• Synthesis of PA-824 analogs
• Identified many new pharmacophores, several of which have demonstrated potent activity against TB
• Optimization has led to nitroimidazole analogs that have in vitro activity greater than PA-824
![Page 27: Public/Private Partnerships in Global Health Initiatives Gerald J. Siuta, Ph.D., CLP](https://reader035.fdocuments.us/reader035/viewer/2022070417/56815455550346895dc26e6d/html5/thumbnails/27.jpg)
GlaxoSmithKline
• Joint drug discovery program at GSK’s Diseases of the Developing World facility in Tres Cantos, Spain
• Five individual projects:– Mycobacterial gyrase inhibitors– InhA inhibitors– Malate synthase inhibitors – Pleuromutilins– Focused screening
![Page 28: Public/Private Partnerships in Global Health Initiatives Gerald J. Siuta, Ph.D., CLP](https://reader035.fdocuments.us/reader035/viewer/2022070417/56815455550346895dc26e6d/html5/thumbnails/28.jpg)
Institute of Materia Medica
• Joint research partnership for the design, synthesis and evaluation of a class of compounds known as riminophenazines– Class was discovered in the 1950s
• The collaboration will utilize IMM's expertise and integrated capabilities in chemistry, pharmacology and manufacture
![Page 29: Public/Private Partnerships in Global Health Initiatives Gerald J. Siuta, Ph.D., CLP](https://reader035.fdocuments.us/reader035/viewer/2022070417/56815455550346895dc26e6d/html5/thumbnails/29.jpg)
Global Alliance for TBDrug Development
www.tballiance.org